Changzhou Qianhong Biopharma Co Ltd
SZSE:002550
Changzhou Qianhong Biopharma Co Ltd
Net Income (Common)
Changzhou Qianhong Biopharma Co Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Changzhou Qianhong Biopharma Co Ltd
SZSE:002550
|
Net Income (Common)
¥200m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
0%
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Net Income (Common)
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Net Income (Common)
¥3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Net Income (Common)
¥4.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
1%
|
CAGR 10-Years
13%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Net Income (Common)
¥4.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
6%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Net Income (Common)
-¥780.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Changzhou Qianhong Biopharma Co Ltd's Net Income (Common)?
Net Income (Common)
200m
CNY
Based on the financial report for Mar 31, 2024, Changzhou Qianhong Biopharma Co Ltd's Net Income (Common) amounts to 200m CNY.
What is Changzhou Qianhong Biopharma Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
0%
Over the last year, the Net Income (Common) growth was -29%.